Skip to main content

ABL, Evivar Strike Cross-license, Marketing Pact

NEW YORK (GenomeWeb News) – Advanced Biological Laboratories has reached cross-license and strategic alliance agreements with Luxembourg-based Evivar, Melbourne, Australia-based ABL said today.

The companies have agreed to develop and commercialize their products, including ABL's TherapyEdge and Evivar's SeqHepB system, for use in management and treatment of HIV and Hepatitis B.

The SeqHepB system is a viral genomics sequence analysis program that is linked to a centralized HBV genomic database. It can be used to identify HBV mutations present in patients and predict their resistance levels to various available medications.

The TherapyEdge is a patient record hospital information system that is used for data and patient management, monitoring, and reporting applications. It also is used for personalized therapy selection, the firms said.

"The combined platforms offer virologists and physicians diagnosing and treating hepatitis and HIV with enhanced clinical and research management tools," Evivar CEO Bernie Romanin said in a statement.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.